Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supreme Court Refuses To Review Pemetrexed Case

Alimta Litigation Revolved Around Doctrine Of Equivalents

Executive Summary

The US Supreme Court has refused a certiorari petition to review a decision involving Dr Reddy’s and Pfizer over Eli Lilly’s Alimta that revolved around the doctrine of equivalents.

You may also be interested in...



Actavis Waits On Alimta Hybrid Following FDA Approval

FDA approval for a hybrid 505(b)(2) new drug application referencing Alimta has been awarded to Teva’s Actavis, with a key patent expiring in May 2022 proving a barrier to market entry. Teva was itself shot down over attempts to launch an ANDA product several years ago.

US Supreme Court Will Not Review Contrave Case

The US Supreme Court has turned down a request by Teva’s Actavis to review a ruling that upheld a patent protecting Nalpropion’s Contrave until 2030, despite the generics firm pointing out that the exact terms of a patent claim were not present in its specification.

Doctrine Of Equivalents Trips Reddy’s And Pfizer On Pemetrexed

Hybrid 505(b)(2) rivals to Lilly’s Alimta from Dr Reddy’s and Pfizer do not literally infringe a key method-of-treatment patent protecting the pemetrexed brand until May 2022. But their alternative salts infringe under the doctrine of equivalents, the US Court of Appeals has confirmed.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB149996

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel